ABVC BioPharma (ABVC) Competitors $2.96 -0.08 (-2.63%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$2.98 +0.02 (+0.84%) As of 10/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABVC vs. NMRA, ALLO, JBIO, TNYA, VTYX, SOPH, TKNO, TECX, ABEO, and AVTEShould you be buying ABVC BioPharma stock or one of its competitors? The main competitors of ABVC BioPharma include Neumora Therapeutics (NMRA), Allogene Therapeutics (ALLO), Jade Biosciences (JBIO), Tenaya Therapeutics (TNYA), Ventyx Biosciences (VTYX), SOPHiA GENETICS (SOPH), Alpha Teknova (TKNO), Tectonic Therapeutic (TECX), Abeona Therapeutics (ABEO), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry. ABVC BioPharma vs. Its Competitors Neumora Therapeutics Allogene Therapeutics Jade Biosciences Tenaya Therapeutics Ventyx Biosciences SOPHiA GENETICS Alpha Teknova Tectonic Therapeutic Abeona Therapeutics Aerovate Therapeutics ABVC BioPharma (NASDAQ:ABVC) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk. Which has more risk & volatility, ABVC or NMRA? ABVC BioPharma has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.92, meaning that its share price is 192% more volatile than the S&P 500. Which has better valuation and earnings, ABVC or NMRA? ABVC BioPharma has higher revenue and earnings than Neumora Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioABVC BioPharma$510K136.62-$4.90M-$0.17-17.41Neumora TherapeuticsN/AN/A-$243.79M-$1.57-1.18 Is ABVC or NMRA more profitable? ABVC BioPharma's return on equity of -46.76% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ABVC BioPharmaN/A -46.76% -23.02% Neumora Therapeutics N/A -98.95%-87.68% Does the media refer more to ABVC or NMRA? In the previous week, ABVC BioPharma and ABVC BioPharma both had 3 articles in the media. ABVC BioPharma's average media sentiment score of 0.83 beat Neumora Therapeutics' score of 0.83 indicating that ABVC BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neumora Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of ABVC or NMRA? 11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 17.1% of ABVC BioPharma shares are held by insiders. Comparatively, 26.8% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate ABVC or NMRA? Neumora Therapeutics has a consensus target price of $7.14, suggesting a potential upside of 284.02%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than ABVC BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Neumora Therapeutics 3 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryNeumora Therapeutics beats ABVC BioPharma on 7 of the 13 factors compared between the two stocks. Get ABVC BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABVC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABVC vs. The Competition Export to ExcelMetricABVC BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.57M$3.36B$6.05B$10.30BDividend YieldN/A2.31%5.73%4.82%P/E Ratio-17.4122.0885.3127.10Price / Sales136.62478.69601.46133.24Price / CashN/A44.9825.7730.18Price / Book49.3310.3812.676.69Net Income-$4.90M-$52.47M$3.32B$276.55M7 Day Performance-8.07%0.18%-0.05%-0.40%1 Month Performance3.86%13.95%8.73%6.53%1 Year Performance491.88%20.83%78.85%41.04% ABVC BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABVCABVC BioPharma0.8514 of 5 stars$2.96-2.6%N/A+527.1%$71.57M$510K-17.4130NMRANeumora Therapeutics2.11 of 5 stars$1.86-1.6%$7.14+284.0%-88.0%$301.23MN/A-1.18108ALLOAllogene Therapeutics2.5564 of 5 stars$1.35-2.2%$8.44+525.5%-52.1%$299.54MN/A-1.22310Analyst DowngradeGap UpJBIOJade Biosciences2.5018 of 5 stars$9.04-1.1%$16.00+77.0%N/A$294.98MN/A-0.3020Gap DownHigh Trading VolumeTNYATenaya Therapeutics2.9901 of 5 stars$1.77+2.9%$6.25+253.1%+11.9%$288.48MN/A-1.84110Gap UpVTYXVentyx Biosciences1.9145 of 5 stars$3.98+6.7%$7.50+88.4%+73.4%$283.81MN/A-2.3730SOPHSOPHiA GENETICS2.2666 of 5 stars$4.16+2.7%$8.00+92.3%+15.1%$281.13M$65.17M-9.45520TKNOAlpha Teknova2.0662 of 5 stars$5.24-7.3%$10.00+90.8%-8.1%$280.39M$37.74M-12.48240TECXTectonic Therapeutic2.7938 of 5 stars$14.91-1.9%$80.29+438.5%-48.7%$278.97MN/A-3.69120ABEOAbeona Therapeutics4.3851 of 5 stars$5.25-1.7%$19.50+271.4%-15.6%$269.22M$400K7.5090News CoverageAnalyst ForecastGap UpAVTEAerovate TherapeuticsN/A$9.14+3.2%N/A-87.8%$264.92MN/A-3.0620High Trading Volume Related Companies and Tools Related Companies Neumora Therapeutics Competitors Allogene Therapeutics Competitors Jade Biosciences Competitors Tenaya Therapeutics Competitors Ventyx Biosciences Competitors SOPHiA GENETICS Competitors Alpha Teknova Competitors Tectonic Therapeutic Competitors Abeona Therapeutics Competitors Aerovate Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABVC) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredNvidia CEO shares biggest regret?Earlier this year I predicted that the only reason Elon was in Washington was to push an AI-first agenda. Sinc...Altimetry | SponsoredBlackRock’s Shocking Crypto MoveBlackRock, Fidelity, and JPMorgan have quietly shifted billions out of Bitcoin and into a single emerging cryp...Weiss Ratings | SponsoredU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ABVC BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ABVC BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
